Presenting marketing results to a medical advisory committee
A medical advisory committee judges marketing the way it judges clinical evidence. Present results in patient order, starting with specialties and conditions, then patient sources, then activity. Separate measured results from inferred ones, show how medical content is reviewed and consented, leave out vanity metrics and competitor comparisons, and bring the committee decisions it can shape. Follow up on every request.
The pattern I keep seeing, and have been guilty of myself, is that a growth leader walks into a room of senior doctors with the deck they would have shown a CEO. Reach, enquiries, cost per lead, a chart going up and to the right. It rarely lands. Nobody is hostile. The doctors are simply unconvinced, and sooner or later one of them asks, politely, how anyone knows that any of it helped a single patient.
That question is the whole brief. A medical advisory committee is not a marketing review and should not be run like one. Its members judge evidence for a living. They are protective of the hospital’s clinical reputation, often sceptical of marketing in principle, and they have far more influence over whether your plans succeed than their formal role suggests. They decide which doctors appear in campaigns, which claims are acceptable and whether a new service is ready to be promoted.
So presenting to them well is not a courtesy. It is how a growth leader earns clinical partnership. This is how I prepare for it now.
What the committee is actually listening for
Doctors on an advisory committee tend to listen for three things, whether or not they say so.
First, safety of reputation. Has anything we published overstated what the hospital or a doctor can do? Has a patient story been used in a way the doctor would be uncomfortable with? Has anything appeared that a peer at another hospital might mock?
Second, honesty of evidence. Are the claims about results defensible? Does the presenter know the difference between correlation and cause? Will they admit what they do not know?
Third, relevance to patients and to their own practice. Did the work bring the right patients, with the right conditions, at the right stage, to the right doctor? Or did it simply bring volume that clogged the OPD with the wrong cases?
A presentation that answers these three questions will be received well even if the results are modest. A presentation that ignores them will struggle even if the results are excellent.
Preparing for a medical advisory committee review
Preparation starts well before the slides. Find out who sits on the committee, what each member cares about and which of them has had a difficult experience with marketing in the past. The medical director is your best guide here, and that relationship deserves investment long before any committee date. I have written about it separately in the growth leader and the medical director.
Then meet two or three members individually a week or two ahead. Show them the draft. Ask what they would challenge. This is not lobbying. It is the same pre-reading any good board paper gets, and it means the committee meeting becomes a discussion rather than an ambush. Doctors who have been consulted in advance are far more likely to defend the work in the room when a colleague questions it.
Finally, agree the purpose of the session with the chair. Is it a periodic update, a request for approval of a new campaign, or a review of content governance? The deck should be built for that purpose and nothing else. Committees lose patience quickly with presentations that try to cover everything.
Lead with patients, not with channels
The single change that improved my committee sessions most was reordering the story. Instead of starting with channels and working down to outcomes, start with patients and work back to what reached them.
Open with the specialties and conditions the hospital set out to grow, and what happened to appointments and admissions in those areas. Then show where those patients came from: search, referrals, word of mouth, camps, corporate tie-ups, insurers. Only then show the marketing activity that supported each route.
This structure does two things. It speaks the committee’s language, because doctors think in terms of patients and cases, not impressions. And it forces honesty, because it makes plain which marketing activity actually connects to patient flow and which does not. If you cannot draw that line for a piece of work, the committee will notice, and it is better that you notice first.
Wherever possible, break results down by doctor and by unit. Doctors want to know whether the work helped their practice. A slide showing that a particular clinic’s new patient appointments rose after its doctor profiles and booking flow were rebuilt will generate more support than any group-level chart.
Be precise about what you can and cannot claim
Doctors are trained to distrust claims that outrun the evidence. Marketing reports routinely do exactly that, and a committee will spot it.
Be explicit about attribution. Say which results are measured directly, such as bookings through the website or calls tracked to a campaign number, and which are inferred, such as a rise in walk-ins during a brand campaign. Say what confounders exist: a new doctor joining, a seasonal pattern, a competitor closing a department, a change in insurer empanelment. The honest version of this is set out in attribution in healthcare: what you can know, and it is worth reading before any committee session.
Use the language of confidence. “We are confident that”, “this suggests”, “we cannot yet tell”. Doctors use this vocabulary themselves and they respect it in others. Nothing damages credibility faster than a presenter who claims a campaign caused a result and is then asked about the new consultant who joined the same month.
If a result was disappointing, say so, and say what you learned. A committee that sees you report failure plainly will trust your successes more.
Show the governance behind the content
For many committee members the most important question is not what the marketing achieved but whether it was safe. Answer it directly with a short section on content governance.
Show how medical content is created and reviewed: who drafts it, which clinician approves it, how long approval takes and how often content is revisited. Show volumes approved and any content withdrawn or corrected, with the reason. Show how patient stories and testimonials are consented and how doctors approve their own profiles and videos. If AI tools are used to draft content, explain exactly how clinical review works around them. The safeguards I rely on are described in AI content at scale without wrecking medical accuracy.
This section often earns more goodwill than the results section. It tells the committee that marketing takes clinical reputation as seriously as they do, and it invites them to improve the process rather than to block the output.
The questions you will get, and how to answer them
After enough of these sessions, the questions become predictable. Preparing answers in advance is simply good manners.
- “Are we bringing the right patients?” Show case mix where you can, not just volume, and be open about where marketing brought enquiries the hospital could not serve well.
- “Why is my colleague in every campaign and I am not?” Explain the criteria for featuring doctors: specialty priorities, availability, capacity and the doctor’s own willingness. Make the criteria visible and fair.
- “Is this ethical?” Explain the rules the team follows on claims, comparisons, pricing language and patient stories, and who enforces them.
- “What does this cost?” Give the budget plainly and connect it to what it supported. Doctors are often surprised by how modest marketing spend is next to equipment or staffing.
- “Why are we advertising at all?” Explain that patients search before they choose, and that a hospital absent from that search leaves the decision to whoever is present.
The last question deserves a calm, non-defensive answer. Some senior doctors believe good medicine should be enough and that marketing cheapens it. Do not argue with the value underneath that belief. Agree that clinical quality is the foundation, and then show how marketing helps patients find that quality rather than replacing it. The case that the brand is bigger than any single doctor is useful context, but put gently in this room.
What to leave out of the deck
Almost as important as what goes in is what stays out. Leave out vanity metrics that have no link to patients, such as follower counts and video views without context. Leave out agency jargon. Leave out any creative that has not been approved through the clinical route, even as a draft example, because it will become the only thing anyone remembers.
Leave out comparisons with named competitors. They invite a debate about the other hospital rather than about your work, and they risk sounding disrespectful to clinical peers who may have trained or worked there.
And leave out anything that looks like a clinical claim. The growth team has no clinical mandate. When a slide needs to describe a treatment or an outcome, use the language the clinicians have approved, and say so.
When the committee should say “not yet”
One of the most valuable things a committee can do for marketing is stop it. Before a new service, a new technology or a new doctor is promoted, the committee is well placed to judge whether the hospital is genuinely ready: whether the team is complete, whether protocols are settled, whether the equipment is commissioned and whether early cases have gone as expected.
Growth teams are under pressure to announce quickly, and the temptation is to treat clinical readiness as someone else’s problem. It is not. A launch that brings patients to a service that is not ready damages the doctors involved, the hospital’s reputation and, in time, the credibility of marketing itself.
So invite the question. For each planned launch or major campaign, bring a short readiness note and ask the committee directly whether it is comfortable. If it is not, agree what would need to be true and when you will return. Committees that are asked this question consistently tend to answer it constructively, and doctors remember which growth leaders asked first rather than announced first.
Turning the committee into a partner
Over time the aim is for the committee to see marketing as something it shapes, not something it polices. That shift happens through small, consistent habits.
Bring the committee decisions, not just reports. Ask it to help prioritise which specialties to promote next, based on clinical readiness and capacity. Ask it to nominate reviewers for each specialty. Ask members which patient questions they hear most often in clinic, and show them later how those questions became content. When doctors see their own knowledge turned into something that helps patients, their view of marketing changes.
Also close the loop on anything the committee raised last time. If a member objected to a piece of content, report what was done about it. If they asked for a breakdown, bring it. A committee that sees its comments acted upon becomes an ally. One that feels ignored becomes an obstacle, and quietly so.
None of this is fast. Earning clinical trust is slow work, and the broader pattern is described in earning the right to change anything. The committee is simply where that trust is tested most visibly.
Your next committee meeting, working backwards
If you have a session coming up, work backwards from the date. Three weeks out, confirm the purpose with the chair and ask the medical director who will be in the room and what worries them. Two weeks out, build the story in patient order: specialties and conditions first, sources of patients second, marketing activity third, governance fourth. Mark every claim as measured or inferred.
A week out, walk two or three members through the draft individually and change it based on what they say. Prepare written answers to the predictable questions. Cut anything that is not needed for the session’s purpose, and check that every piece of content shown has passed clinical review.
On the day, keep the presentation short and the discussion long. Take notes on every request. Within a few days, send a brief written summary of what was agreed and what you will bring next time. If you want a shared view of planned content to discuss with the committee between meetings, the healthcare content calendar template is a simple starting point.
Done this way, the medical advisory committee stops being the meeting you survive and becomes the meeting that makes your work credible across the hospital.
Questions people ask
A medical advisory committee is a group of senior clinicians who advise hospital leadership on clinical matters. In a marketing context, it typically reviews how the hospital presents its doctors, services and outcomes to the public, approves or shapes medical content, and helps decide which specialties are ready to promote. Presenting to it well is how a growth leader earns clinical partnership.
Because clinical reputation is the hospital’s most valuable asset and doctors are its guardians. Regular reporting gives the committee visibility of what is published in the hospital’s name and a chance to shape it. It also builds support among senior doctors, whose cooperation marketing needs for profiles, videos, reviews and new service launches. It also reduces the chance of a public surprise.
Often enough to build familiarity, but not so often that it becomes routine noise. A periodic update aligned with the committee’s regular calendar usually works, with additional sessions when a major campaign, a new service launch or a significant content policy change needs clinical input. The chair and medical director can advise on what rhythm suits the committee.
Doctors care about whether the right patients reached the right doctor at the right stage. Case mix, appointments and admissions in priority specialties, and the effect on individual clinics matter far more to them than reach or engagement. Results broken down by doctor and unit tend to generate the most useful discussion and the strongest support.
Do not argue with the value underneath the concern. Agree that clinical quality comes first, then explain the rules the team follows on claims, comparisons, pricing language and patient stories, and who enforces them. Show that marketing helps patients find good care rather than replacing it. Inviting the doctor to review content often converts scepticism into partnership.
The medical director can brief the growth leader on committee members, their concerns and any past friction with marketing. They can also help set the session’s purpose with the chair, review the draft for clinical sensitivity and support the presenter in the room. Their visible backing signals to the committee that the work has been done responsibly.
Be explicit about what is measured directly and what is inferred. Name the confounders, such as new doctors joining, seasonal patterns or insurer changes. Use the language of confidence that clinicians themselves use. Admitting uncertainty builds far more credibility with doctors than a confident claim that falls apart under a single question. Say plainly when you simply do not know.
Show only creative that has passed clinical review, and show it in the context of the governance process that approved it. Unapproved drafts tend to dominate the discussion and can undermine trust. If you want input on work in progress, share it with individual members or specialty reviewers beforehand rather than in the full committee.
The CFO gains confidence that marketing spend is supporting specialties the clinicians consider ready and valuable, and that reputational risk is being managed. Committee input on which services to promote also helps align spend with capacity and margin. The CFO may attend or receive the summary, but the committee’s focus stays clinical. That alignment is worth a great deal to finance.
It takes several cycles of meetings, not one strong presentation. Trust grows as members see honest reporting, sensible content governance and follow-through on their comments. A single strong presentation helps, but consistency matters more. Growth leaders who close the loop on every request usually find the committee becomes supportive over time. Patience is part of the job here.
Plan meaningful effort spread over a few weeks before each session: understanding the members, meeting some individually, building the story in patient order, marking every claim as measured or inferred, and preparing answers to predictable questions. The effort is worth it, because the committee’s view influences how the whole medical staff regards marketing. Treat it as part of the job, not an extra.
Yes, if it has passed the same clinical review as any other content, and if you explain how AI is used and controlled. Doctors are rightly cautious about AI in medical communication. Be transparent about which steps are automated, who reviews the output and how errors are caught and corrected before publication. Invite questions and welcome scrutiny.
Avoid vanity metrics without patient relevance, agency jargon, unapproved creative, comparisons with named competitor hospitals and anything resembling a clinical claim made by the marketing team. Each of these distracts from the discussion or damages credibility with clinicians. Keep the deck focused on patients, evidence and governance. When in doubt, leave it out of the deck entirely.
Send a short written summary within a few days listing what was agreed, what was requested and when you will report back. Act on each request and report progress at the next session. This follow-through signals respect for the committee’s time and is the single habit that most improves its relationship with marketing. Then keep the cycle going.
